Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | CDC25A | P30304 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9224636 | 0.85 | DRD2 (0.77) | NPC1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1544895 | 0.81 | ALDH1A1 (0.67) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6409127 | 0.80 | SMN1; SMN2 (0.80) | NPC1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17712729 | 0.80 | HDAC3 (0.69) | NPC1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16944479 | 0.80 | SMN1; SMN2 (1.00) | NPC1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6405090 | 0.79 | ALDH1A1 (0.72) | MEN1KMT2ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL6404779 | 0.78 | SMN1; SMN2 (0.80) | NPC1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16944458 | 0.78 | SMN1; SMN2 (0.80) | NPC1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6408827 | 0.77 | TSHR (0.62) | NPC1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL22019056 | 0.77 | GAA (0.60) | NPC1MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110295016-A1 | A NEW PROCESS FOR PREPARING 4-[4-METHYL-5-(CL-10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO)-4H-1,2,4-TRIAZOL-3-YL]PYRIDINES | ASTRAZENECA AB (SE) | 2011-12-01 | — | — | US | disclosed |
| EP-2376474-A1 | A NEW PROCESS FOR PREPARING 4- Ý4-METHYL-5- (CL- 10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO) -4H-1, 2, 4-TRIAZOL-3- YL¨PYRIDINES. | AstraZeneca AB (SE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068172-A1 | A NEW PROCESS FOR PREPARING 4- [4-METHYL-5- (CL- 10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO) -4H-1, 2, 4-TRIAZOL-3- YL] PYRIDINES. | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068172-A1 | A NEW PROCESS FOR PREPARING 4- [4-METHYL-5- (CL- 10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO) -4H-1, 2, 4-TRIAZOL-3- YL] PYRIDINES. | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295016-A1 | A NEW PROCESS FOR PREPARING 4-[4-METHYL-5-(CL-10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO)-4H-1,2,4-TRIAZOL-3-YL]PYRIDINES | NT5C, CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NPC1 2969/4885MEN1 3630/4885KMT2A 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.